Genetic studies have shown that KHK LOF mutations are beneficial for fructose excretion, and inhibition of KHK can be used in the treatment of NAFLD/NASH by effectively suppressing fructose metabolism and its contribution to lipid accumulation, oxidative stress, inflammation, and insulin resistance. Here, KHK is linked to metabolic dysfunction-associated steatotic liver disease.